MDT

81.42

-1.31%↓

VEEV

208.52

-3.3%↓

A

99.74

-2.56%↓

WBA

10.84

-0.37%↓

CHE

558.79

-3.59%↓

MDT

81.42

-1.31%↓

VEEV

208.52

-3.3%↓

A

99.74

-2.56%↓

WBA

10.84

-0.37%↓

CHE

558.79

-3.59%↓

MDT

81.42

-1.31%↓

VEEV

208.52

-3.3%↓

A

99.74

-2.56%↓

WBA

10.84

-0.37%↓

CHE

558.79

-3.59%↓

MDT

81.42

-1.31%↓

VEEV

208.52

-3.3%↓

A

99.74

-2.56%↓

WBA

10.84

-0.37%↓

CHE

558.79

-3.59%↓

MDT

81.42

-1.31%↓

VEEV

208.52

-3.3%↓

A

99.74

-2.56%↓

WBA

10.84

-0.37%↓

CHE

558.79

-3.59%↓

Search

Alkermes PLC

Ouvert

SecteurSoins de santé

27.22 0.44

Résumé

Variation du prix de l'action

24h

Actuel

Min

26.6

Max

27.76

Chiffres clés

By Trading Economics

Revenu

54M

147M

Ventes

52M

430M

P/E

Moyenne du Secteur

12.518

59.668

BPA

1.05

Marge bénéficiaire

34.072

Employés

1,800

EBITDA

58M

181M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+44.7% upside

Dividendes

By Dow Jones

Prochains Résultats

1 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-562M

4.5B

Ouverture précédente

26.78

Clôture précédente

27.22

Sentiment de l'Actualité

By Acuity

50%

50%

144 / 385 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

Alkermes PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

19 avr. 2025, 01:45 UTC

Résultats

Preview -- Barron's

18 avr. 2025, 15:57 UTC

Principaux Mouvements du Marché

Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch

20 avr. 2025, 22:32 UTC

Actualités

Stocks Poised for Lower Open -- Barrons.com

20 avr. 2025, 18:43 UTC

Actualités

Chicago Fed's Goolsbee Has a Warning About Independence -- Barrons.com

20 avr. 2025, 18:00 UTC

Actualités

Tesla, Alphabet, Verizon, Chipotle, IBM, Boeing, and Many More Stocks to Watch This Week -- Barrons.com

20 avr. 2025, 13:00 UTC

Actualités

Airbus Promised a Green Aircraft. That Bet Is Now Unraveling. -- WSJ

20 avr. 2025, 06:00 UTC

Actualités

Foreign Stocks Are Beating the U.S. Market. Here's How Much You Should Have in Your Portfolio. -- Barrons.com

20 avr. 2025, 03:00 UTC

Actualités

Putin's War Economy Can't Escape Trump's Trade Blitz -- WSJ

20 avr. 2025, 02:00 UTC

Actualités

Who Will Pay the Price for Trump's Economic Goals? -- WSJ

19 avr. 2025, 02:00 UTC

Actualités

Tomatoes Become One of the First Everyday Casualties of Trade War -- WSJ

19 avr. 2025, 02:00 UTC

Actualités

Beijing Stokes Patriotic Fervor and Blames U.S. for Trade War -- WSJ

18 avr. 2025, 20:42 UTC

Acquisitions, Fusions, Rachats

What Bill Ackman Sees in Hertz and Why He's Betting Big on the Rental-Car Company -- Barrons.com

18 avr. 2025, 20:32 UTC

Actualités

Trump to Replace Acting IRS Commissioner -- 2nd Update

18 avr. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 avr. 2025, 19:52 UTC

Market Talk

Correction to Aluminum Fee Rising Slower Than Forecast Article

18 avr. 2025, 19:40 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

18 avr. 2025, 19:40 UTC

Market Talk

Aluminum Fee Rising Slower Than Forecast From Tariff -- Market Talk

18 avr. 2025, 18:51 UTC

Résultats

Netflix Has Made Several Risky Bets. Earnings Show They've Paid Off. -- Barrons.com

18 avr. 2025, 18:40 UTC

Acquisitions, Fusions, Rachats

What Bill Ackman Sees in Hertz and Why He's Betting Big on the Rental-Car Company -- Barrons.com

18 avr. 2025, 18:29 UTC

Market Talk

Shorter Duration Seen as Way to Shield Portfolio From Political Turbulence -- Market Talk

18 avr. 2025, 18:21 UTC

Actualités

Ford Halts Shipments of F-150s and Other Models to China -- WSJ

18 avr. 2025, 17:31 UTC

Actualités

Trump to Replace Acting IRS Commissioner -- WSJ

18 avr. 2025, 17:24 UTC

Acquisitions, Fusions, Rachats

Capital One's Discover Takeover Gets the Green Light. The Two Will Create the 6th-Largest U.S. Bank. -- Barrons.com

18 avr. 2025, 17:22 UTC

Acquisitions, Fusions, Rachats

Capital One's $35 Billion Discover Takeover Clears Final Approvals -- Barrons.com

18 avr. 2025, 16:00 UTC

Actualités

Trump's Trade War Threatens One of America's Top Energy Exports -- WSJ

18 avr. 2025, 15:53 UTC

Actualités
Acquisitions, Fusions, Rachats

Bill Ackman Teases Prospect of Uber, Hertz Partnership -- Update

18 avr. 2025, 15:46 UTC

Résultats

Tech's Problems in China Are Getting Worse. These Companies Are Most at Risk. -- Barrons.com

18 avr. 2025, 15:10 UTC

Market Talk
Résultats

Netflix Momentum Likely To Continue Thanks To Growing Subscriber Base -- Market Talk

18 avr. 2025, 14:46 UTC

Résultats

Tech Earnings Have Good News for Chip Stocks, So Far. And 1 Warning. -- Barrons.com

18 avr. 2025, 14:24 UTC

Market Talk
Résultats

Netflix Still Has Room to Add Subscribers -- Market Talk

Comparaison

Variation de prix

Alkermes PLC prévision

Objectif de Prix

By TipRanks

44.7% hausse

Prévisions sur 12 Mois

Moyen 39.07 USD  44.7%

Haut 52 USD

Bas 30 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

14 ratings

8

Achat

6

Maintien

0

Vente

Score Technique

By Trading Central

26.98 / 27.04Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

144 / 385Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.